Evidence about the relative risks and benefits of thiazolidinediones, such as rosiglitazone and pioglitazone, for the treatment of type 2 diabetes mellitus has been inconsistent. Meta-analyses and epidemiologic reviews suggest that rosiglitazone may increase cardiovascular risk, but two randomized trials do not. A novel epidemiologic analysis has been a focal point of recent FDA deliberations on this issue.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yki-Järvinen, H. Thiazolidinediones. N. Engl. J. Med. 351, 1106–1118 (2004).
Singh, S., Loke, Y. K. & Furberg, C. D. Thiazolidinediones and heart failure. A teleo-analysis. Diabetes Care 30, 2148–2153 (2007).
Loke, Y. K., Singh, S. & Furberg, C. D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180, 32–39 (2009).
Nissen, S. E. & Wolski, K. Rosiglitazone revisited. An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170, 1191–1201 (2010).
Mannucci, E. et al. Cardiac safety profile of rosiglitazone. A comprehensive meta-analysis of randomized clinical trials. Int. J. Cardiol. doi:10.1016/j.ijcard.2009.01.064.
Graham, D. J. et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411–418 (2010).
Home, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 373, 2125–2135 (2010).
The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360, 2503–2515 (2009).
Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002).
The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981–2997 (2002).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares an association with the following companies: Amylin Pharmaceuticals (grant or research support/ consultant/ lecture honoraria), Eli Lilly (grant or research support/ consultant/ lecture honoraria), GlaxoSmithKline (grant or research support), Pfizer (consultant), Hoffman–La Roche (consultant), Sanofi-aventis (grant or research support/ consultant/ lecture honoraria). In addition to the above, M. C. Riddle serves on the Steering Committee of the TIDE trial, and is one of the clinical site investigators for TIDE. TIDE is supported by GlaxoSmithKline and operated by Population Health Research Institute at McMaster University, Hamilton, Ontario.
Rights and permissions
About this article
Cite this article
Riddle, M. What evidence should guide the use of thiazolidinediones?. Nat Rev Endocrinol 6, 600–602 (2010). https://doi.org/10.1038/nrendo.2010.156
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.156
